|DB00004||Denileukin diftitox||For treatment of cutaneous T-cell lymphoma|
|DB00008||Peginterferon alfa-2a||Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have
compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].|
|DB00011||Interferon alfa-n1||For treatment of venereal or genital warts caused by the Human Papiloma Virus|
|DB00012||Darbepoetin alfa||For the treatment of anemia (from renal transplants or certain HIV treatment)|
|DB00016||Erythropoietin||Indicated in adult and paediatric patients for the:
- treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.
- treatment of anemia due to zidovudine in patients with HIV-infection.
- treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
- reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.|
|DB00018||Interferon alfa-n3||For the intralesional treatment of refractory or recurring external condylomata acuminata.|
|DB00019||Pegfilgrastim||Pegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure.|
|DB00020||Sargramostim||For the treatment of cancer and bone marrow transplant|
|DB00022||Peginterferon alfa-2b||Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
|DB00026||Anakinra||For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). |
|DB00033||Interferon gamma-1b||Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.|
|DB00034||Interferon Alfa-2a, Recombinant||For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.|
|DB00038||Oprelvekin||Indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.[Label]|
|DB00041||Aldesleukin||For treatment of adults with metastatic renal cell carcinoma.|
|DB00060||Interferon beta-1a||For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum|
|DB00068||Interferon beta-1b||Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.|
|DB00069||Interferon alfacon-1||For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma|
|DB00105||Interferon alfa-2b||For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.|
|DB05258||Interferon alfa||Investigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.|
|DB05305||Cintredekin Besudotox||Investigated for use/treatment in brain cancer.|
|DB05332||Romiplostim||Treatment of chronic immune thrombocytopenic purpura. |
|DB05396||Albinterferon Alfa-2B||Investigated for use/treatment in hepatitis (viral, C).|
|DB05718||Maxy-G34||Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.|
|DB05934||CTCE-0214||Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases.|
|DB06534||Thrombopoietin||Investigated for use/treatment in thrombocytopenia.|
|DB06562||Emfilermin||Investigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility.|
|DB09103||Ancestim||Ancestim, in combination with filgrastim, is indicated for the setting of autologous peripheral blood progenitor cell transplantation in patients at risk of poor peripheral blood progenitor cell mobilisation.[L1090] The use of ancestim with filgrastim will generate a sustained increase in the number of peripheral blood progenitor cells capable of engraftment. It is used for mobilization of progenitor cells from the bone marrow to the peripheral blood with or withouth mobilizing chemotherapy. The harvested progenitor cells can be used for transplant following myelosuppressive or myeloablative therapies.[L1089]|
|DB09107||Methoxy polyethylene glycol-epoetin beta||For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.|
|DB09122||Peginterferon beta-1a||For the treatment of patients with relapsing forms of multiple sclerosis.|
|DB11624||Epoetin delta||Not Available|
|DB13144||Lenograstim||The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy.
Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy.
Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion.
GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).|
|DB13200||Lipegfilgrastim||Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441]. |
|DB14076||Interleukin-1 alpha, human recombinant||Not Available|
|DB05386||Regramostim||Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.|
|DB14767||Peginterferon lambda-1a||Not Available|
|DB14865||Human interleukin-2||Not Available|
|DB14999||Human interferon beta||Not Available|
|DB15015||Recombinant CD40-ligand||Not Available|
|DB15131||Interferon alfa-2c||Not Available|
|DB15402||Tucotuzumab celmoleukin||Not Available|
|DB15443||Lorukafusp alfa||Not Available|